Inspec

Inspec Free Cash Flow

The Free Cash Flow (FCF) of Inspec (6656.T) as of Oct 29, 2026 is -574.21 M JPY. In the previous year, Free Cash Flow (FCF) was 459.26 M JPY — a change of -225.03% (lower).

Free Cash Flow

-574.21 MJPY

YoY

-225.03%

Last updated:

Free Cash Flow (FCF) of Inspec is 2026 -574.21 M JPY. Free Cash Flow (FCF) of Inspec was 2025 459.26 M JPY. It decreases by -225.03% lower compared to the previous year.

The Inspec Free Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Free Cash Flow
Date
Free Cash Flow
Jan 1, 2019
437.89 M JPY
Jan 1, 2020
-378.71 M JPY
Jan 1, 2021
-300.24 M JPY
Jan 1, 2022
-475.51 M JPY
Jan 1, 2023
-722.67 M JPY
Jan 1, 2024
19.43 M JPY
Jan 1, 2025
459.26 M JPY
Jan 1, 2026
-574.21 M JPY
The Inspec Free Cash Flow history
YEARFree Cash FlowYoY
-574.21 MJPY-225.03%
459.26 MJPY+2,263.08%
19.43 MJPY-102.69%
-722.67 MJPY+51.98%
-475.51 MJPY+58.38%
-300.24 MJPY-20.72%
-378.71 MJPY-186.49%
437.89 MJPY-182.57%
-530.31 MJPY-300.48%
264.52 MJPY+177.64%
95.28 MJPY-181.50%
-116.90 MJPY-44.93%
-212.28 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inspec Stock analysis

What does Inspec do? inspec Inc. generates revenue through three primary segments. The Semiconductor Package Substrates and Precision Substrate Inspection Equipment segment sells appearance inspection equipment for semiconductor package substrates and precision printed circuit boards used in smartphones, tablets, PCs, and wearable terminals. The Precision Substrate Manufacturing Equipment segment provides photoplotters, inkjet printers, and direct imaging devices along with maintenance services for printed circuit boards. The Digital Pathology Related Equipment segment develops and sells medical image processing systems, specifically whole slide imaging (WSI) for digital pathology applications. Customers include manufacturers of advanced digital devices requiring semiconductor inspection, PCB producers needing photoplotters and imaging devices, and healthcare providers utilizing whole slide imaging systems for pathology diagnostics. The company's products target the semiconductor, electronics manufacturing, and medical imaging sectors with specific applications in device assembly, PCB production, and medical diagnostics. inspec Inc. focuses on equipment for semiconductor package substrates, precision substrates, and digital pathology, serving clients in the electronics and healthcare industries. The firm's inspection and imaging solutions are tailored to meet the quality control needs of high-tech manufacturing and medical diagnostics, with no mention of additional revenue streams beyond these three segments. Inspec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inspec stock

Free Cash Flow (FCF) of Inspec is -574.21 M JPY in 2026.

Free Cash Flow (FCF) of Inspec changed from 459.26 M JPY to -574.21 M JPY, representing a -225.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow (FCF) Inspec since 2006 – with annual values, charts, and detailed analysis.

Free Cash Flow is the cash available after capital expenditures. It represents the cash a company can use for dividends, debt reduction, or reinvestment.

FCF = Operating Cash Flow - Capital Expenditures

Free Cash Flow (FCF)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Free Cash Flow (FCF)'s Inspec historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Inspec

All Key Metrics — Inspec